Piracetam
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
20
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Memory Disorders
Conditions
Memory Disorders
Trial Timeline
May 1, 2000 → Jan 1, 2004
NCT ID
NCT00567060About Piracetam
Piracetam is a pre-clinical stage product being developed by UCB for Memory Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00567060. Target conditions include Memory Disorders.
Hype Score Breakdown
Clinical
5
Activity
2
Company
7
Novelty
2
Community
1
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00567060 | Pre-clinical | Completed |
| NCT01883011 | Approved | Terminated |
Competing Products
8 competing products in Memory Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Donepezil Hydrochloride + Placebo | Eisai | Approved | 85 |
| Roflumilast + Roflumilast placebo + Donepezil + Donepezil placebo + Scopolamine | AstraZeneca | Phase 1 | 33 |
| Aricept + IFN-alpha2A | Pfizer | Phase 2 | 51 |
| Tolterodine ER + Oxybutynin ER | Pfizer | Approved | 84 |
| Levetiracetam, Keppra | UCB | Approved | 82 |
| EGb 761® (Tanakan®) | Ipsen | Approved | 82 |
| LX6171 High Dose + LX6171 Low Dose + Placebo | Lexicon Pharmaceuticals | Phase 2 | 47 |
| Fruitflow-II + resVida | Brain Biotech | Pre-clinical | 15 |